• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Aminophenyl ethers
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

4-Amino-2-fluoro-5-methoxybenzonitrile (CAS No. 1441723-24-5): An Emerging Compound in Pharmaceutical Research

4-Amino-2-fluoro-5-methoxybenzonitrile (CAS No. 1441723-24-5) is a versatile organic compound that has garnered significant attention in recent years due to its potential applications in pharmaceutical and medicinal chemistry. This compound, characterized by its unique structural features, including an amino group, a fluorine atom, and a methoxy substituent, offers a promising platform for the development of novel therapeutic agents.

The chemical structure of 4-Amino-2-fluoro-5-methoxybenzonitrile consists of a benzene ring with specific functional groups that confer distinct chemical and biological properties. The presence of the amino group enhances the compound's reactivity and potential for forming hydrogen bonds, which is crucial for interactions with biological targets. The fluorine atom, known for its electron-withdrawing effect, can influence the compound's lipophilicity and metabolic stability. The methoxy group, on the other hand, can modulate the compound's solubility and electronic properties.

Recent studies have explored the potential of 4-Amino-2-fluoro-5-methoxybenzonitrile in various therapeutic areas. One notable application is in the development of anti-inflammatory drugs. Research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent anti-inflammatory activity by inhibiting key enzymes involved in the inflammatory pathway. These findings suggest that 4-Amino-2-fluoro-5-methoxybenzonitrile could serve as a lead compound for designing more effective anti-inflammatory agents.

In addition to its anti-inflammatory properties, 4-Amino-2-fluoro-5-methoxybenzonitrile has also shown promise in cancer research. A study published in Cancer Research demonstrated that certain derivatives of this compound can selectively inhibit cancer cell proliferation by targeting specific signaling pathways. This selective inhibition is crucial for minimizing side effects and improving treatment outcomes. The unique combination of functional groups in 4-Amino-2-fluoro-5-methoxybenzonitrile allows for fine-tuning of its biological activity, making it a valuable starting point for drug discovery efforts.

The synthetic accessibility of 4-Amino-2-fluoro-5-methoxybenzonitrile is another factor contributing to its appeal in pharmaceutical research. Several efficient synthetic routes have been developed to produce this compound and its derivatives. For instance, a one-pot synthesis method using readily available starting materials has been reported, which significantly reduces the cost and complexity of large-scale production. This synthetic flexibility enables researchers to rapidly generate a diverse library of compounds for high-throughput screening and optimization.

The physicochemical properties of 4-Amino-2-fluoro-5-methoxybenzonitrile, such as its solubility, stability, and bioavailability, are critical factors that influence its suitability as a drug candidate. Studies have shown that this compound exhibits favorable pharmacokinetic profiles, including good oral bioavailability and low toxicity. These properties are essential for ensuring that the drug reaches its intended target in sufficient concentrations without causing adverse effects.

In conclusion, 4-Amino-2-fluoro-5-methoxybenzonitrile (CAS No. 1441723-24-5) represents an exciting opportunity in pharmaceutical research. Its unique chemical structure and versatile biological activities make it a promising lead compound for developing novel therapeutic agents. Ongoing research continues to uncover new applications and optimize its properties, paving the way for innovative treatments in various medical fields.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)